Table 3.

Adverse events ≥ 15%, reported within 8 weeks of infusion (infused patients, N = 9)

AEs (regardless of study drug relationship)	Patients (N = 9)
	All grades, n (%)	Grade 3, n (%)	Grade 4, n (%)
Cytokine release syndrome	6 (66.7)	2 (22.2)	0
Anemia	4 (44.4)	2 (22.2)	0
Decreased neutrophil count	4 (44.4)	2 (22.2)	2 (22.2)
Decreased white blood cell count	4 (44.4)	2 (22.2)	1 (11.1)
Decreased lymphocyte count	3 (33.3)	1 (11.1)	2 (22.2)
Decreased platelet count	3 (33.3)	1 (11.1)	1 (11.1)
Decreased appetite	3 (33.3)	1 (11.1)	0

AEs are based on MedDRA preferred term

AE adverse event, MedDRA Medical Dictionary for Regulatory Activities